Previous 10 | Next 10 |
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with patient-reported pain improvements NYX-2925 was well tolerated with no serious adverse events ...
"A diplomatic statement ... is a statement of which everything is true but the sentiment which seems to prompt it .” ― Joseph Conrad, Victory My regular readers know I rarely look at new IPOs until they are public for at least 18 months. So many of these small cap names, esp...
Aptinyx Inc. (APTX) Q1 2019 Earnings Conference Call May 14, 2019 08:00 ET Company Participants Nick Smith - Senior Director, Corporate Development Norbert Riedel - President & CEO Ashish Khanna - CFO & Chief Business Officer Andy Kidd - COO Conference Call Participa...
Aptinyx (NASDAQ: APTX ): Q1 GAAP EPS of -$0.50 misses by $0.04 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill., May 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical co...
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Henry O. Gosebruch to its board of directors,...
EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live we...
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is up 6% premarket on average volume in response to its announcement of positive data from a Phase 1 study assessing NYX-458, in development for the treatment of cognitive impairment associated with Parkinson's disease, in 62 heal...
Favorable overall safety, tolerability, and pharmacokinetic profile — no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at preclinically efficacious doses Expect to initiate Phase 2a study in patients wit...
M echanism of NYX-2925 is highly relevant in advanced DPN patients with longer duration of chronic pain Results support and inform future Phase 2 study, initiation expected in 2019 EVANSTON, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage bio...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...